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Abstract
Recently, the covalent binding of a cholesterol moiety to a classical HIV-1 fusion inhibitor peptide, C34, was shown to
potentiate its antiviral activity. Our purpose was to evaluate the interaction of cholesterol-conjugated and native C34 with
membrane model systems and human blood cells to understand the effects of this derivatization. Lipid vesicles and
monolayers with defined compositions were used as model membranes. C34-cholesterol partitions more to fluid phase
membranes that mimic biological membranes. Importantly, there is a preference of the conjugate for liquid ordered
membranes, rich in cholesterol and/or sphingomyelin, as observed both from partition and surface pressure studies. In
human erythrocytes and peripheral blood mononuclear cells (PBMC), C34-cholesterol significantly decreases the membrane
dipole potential. In PBMC, the conjugate was 14- and 115-fold more membranotropic than T-1249 and enfuvirtide,
respectively. C34 or cholesterol alone did not show significant membrane activity. The enhanced interaction of C34-
cholesterol with biological membranes correlates with its higher antiviral potency. Higher partitions for lipid-raft like
compositions direct the drug to the receptor-rich domains where membrane fusion is likely to occur. This intermediary
membrane binding step may facilitate the drug delivery to gp41 in its pre-fusion state.
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Introduction
The development of new drugs against the human immunode-
ficiency virus type 1 (HIV-1) has been the focus of intense research
since its discovery [1]. The virus fusion with the cell membrane
and the consequent entry into the host cell is a critical moment of
its life cycle. Efficiently blocking this process prevents all the
subsequent intracellular steps. Most importantly, the integration of
the viral genome, which can stay silent for years, does not occur.
Despite this promising approach, only two HIV entry inhibitors
are available in the market: maraviroc, an inhibitor of envelope
binding to the CCR5 co-receptor [2], and enfuvirtide, a fusion
inhibitor peptide targeting gp41 in its pre fusion conformation [3].
Enfuvirtide, due to its peptide nature, has to be administered
subcutaneously and is more sensitive to degradation while in
circulation. It is important to overcome these limitations as peptide
drugs can also have the advantage to be potentially less toxic.
Several HIV-1 fusion inhibitor peptides have been developed
and studied in vitro [4–6]. The rationale for the development of
these peptides is based on the structural rearrangements of gp41
after the binding of gp120 to CD4 and a co-receptor (CCR5 or
CXCR4). The two heptad repeats fold into each other creating a
hairpin structure (also named 6-helix bundle, due to the formation
of a homotrimer of heterodimers) that brings the two membranes
together and promotes the formation of the fusion pore used for
the entry of the viral content into the target cell [7]. Most of these
peptides were derived from the C-terminal heptad repeat (CHR)
region of gp41, and hence bind to the opposite domain in order to
prevent bundle formation. The rational design of higher efficacy
peptides compared to the native sequence from gp41 CHR
include rearrangements and substitutions in order to improve
intrinsic characteristics such as solubility, helical stability, oligo-
merization, lipophilicity and resistance to proteolysis [4].
In our previous works, we emphasized the importance of the
lipophilicity and membrane interaction properties of the fusion
inhibitor peptides enfuvirtide, T-1249 and sifuvirtide [8–10]. The
fact that these peptides can partition to the membranes and to the
microdomains, where receptors are preferentially located, facili-
tates the interaction with gp41 in its exposed conformation. This
intermediate is temporally and spatially constrained; thus, a pre-
concentration effect in the membrane can be a strategy to
overcome this poorly accessible target.
Previously, the peptide C34, a classical fusion inhibitor used also
as a template for the structural characterization of gp41 [7], was
conjugated with a cholesterol moiety in order to obtain higher
efficacy and lifetime in vivo [11]. C34-cholesterol (with cholesterol
covalently bound to the C-terminus of the peptide; also known as
L’644) was shown to be 50-fold more potent than C34 alone in
terms of IC50 (HXB2 strain). Moreover, in a mouse model, the
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conjugated peptide was still detected 24 h after injection and with
higher concentration, when compared with the unconjugated
peptide, which was undetectable after 6 h [11]. In another recent
work, a comparative pre-clinical evaluation of four fusion
inhibitors (C34, T1249, enfuvirtide and C34-cholesterol) as
potential microbicides showed that C34-cholesterol exhibits the
highest anti HIV-1 activity as well as an extended window of
activity. Moreover, C34-cholesterol is able to inhibit both wild
type and reverse transcriptase inhibitors-resistant isolates [12].
The conjugation approach to improve fusion inhibitor peptides,
such as by attaching acyl chains of various sizes [13–15] or human
serum albumin [16,17], has been tried before; however, none has
reached beyond pre-clinical tests. C34-cholesterol is a promising
candidate [12].
In this article, we aimed at characterizing the interaction of C34
and C34-cholesterol with biomembranes to elucidate the peptide-
membrane interaction and possible relations with the efficiency of
these drugs. Our approach first covered a detailed study of the
peptide partition towards biomembrane model systems, namely
large unilamellar vesicles (LUV), by following the intrinsic
fluorescence changes of the peptide tryptophan residues, located
at the N-terminal region, when it adsorb or penetrate in the lipid
environment. This methodology allows testing a diversity of lipid
compositions, in order to dissect the role of the different lipid
types. Insertion of the fusion inhibitors in lipid monolayers was
also evaluated on a Langmuir-Blodgett trough. Finally, we studied
the interaction with membranes of human blood cells, in an ex vivo
setting. In this case, we used a lipophilic fluorescent probe (di-8-
ANEPPS) that is sensitive to the membrane dipole potential and





was obtained from the NIH AIDS Research and Reference
Reagent Program (Division of AIDS, NIAID, NIH). C34-
cholesterol (L’644) was a kind gift from the International
Partnership for Microbicides (licensed by Merck) and its sequence
is C34-GSGC-Cholesterol. 5NS (5-doxyl-stearic acid) and 16NS
(16-doxyl-stearic acid) were from Aldrich (Milwaukee, WI, USA).
L-Tryptophan, acrylamide, HEPES and NaCl were from Merck




line), SM (egg sphingomyelin), POPE (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine) and POPS (1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-L-serine) were purchased from Avanti Polar
Lipids (Alabaster, AL, USA), while cholesterol (Chol) were from
Sigma (St. Louis, MO, USA).
Fluorescence Spectroscopy Measurements
C34 and C34-cholesterol peptides contain tryptophan residues,
which make fluorescence techniques suitable tools to probe these
molecules. The working buffer used throughout the studies was
HEPES 10 mM pH 7.4 in NaCl 150 mM. C34 (150 mM) and Trp
(500 mM) stock solutions were prepared in buffer. C34-cholesterol
(500 mM) stock solutions were prepared in DMSO. Large
unilamellar vesicles (LUV) were prepared by extrusion methods,
as described elsewhere [18,19].
Membrane partition and fluorescence quenching studies using
acrylamide were carried out in a Varian Cary Eclipse fluorescence
spectrophotometer (Mulgrave, Australia) and time-resolved fluo-
rescence spectroscopy studies in a LifeSpec II Fluorescence
Lifetime spectrometer (Edinburgh Instruments).
The fluorescence spectral characterization of C34, C34-
cholesterol and Trp was performed with an excitation wavelength
of 280 nm, except for 5NS, 16NS and acrylamide quenching
experiments, where the excitation was performed at 290 nm to
minimize the relative quencher/fluorophore light-absorption
ratios. For the quenching experiments, fluorescence emission was
collected at a fixed wavelength of 350 nm and for the partition
studies integrated spectra from 310 to 450 nm were used. Typical
spectral bandwidths were 5 nm for excitation and 10 nm for
emission. Excitation and emission spectra were corrected for
wavelength-dependent instrumental factors [20]. During the
quenching and partition experiments, emission was also corrected
for successive dilutions, scatter [21] and simultaneous light
absorptions of quencher and fluorophore. All the fluorescence
measurements in this study were performed at room temperature
(approximately 25uC).
Partition Coefficient Determination
Membrane partition studies were performed by successive
additions to a 5 mM C34 or C34-cholesterol solution of small
amounts of LUV suspensions with different lipid compositions,
including: POPC, POPC:Chol (2:1 and 1:1), DPPC, POPC:-
Chol:SM (1:1:1 and 2:2:1), POPC:SM (2:1), POPC:POPG (5:1),
POPC:DHSM (1:0.06), and HIV membrane-like mixture with
and without DHSM (POPC 5.3%, DPPC 3.5%, cholesterol
45.3%, SM 18.2%, POPE 19.3% and POPS 8.4% [22]), with a
10 min incubation time between each addition. The partition










where IW and IL are the fluorescence intensities in aqueous
solution and in lipid, respectively, cL is the molar volume of the
lipid [24,25], and [L] its concentration.
Surface Pressure
Changes on the surface pressure of lipid monolayers induced by
C34, C34-cholesterol, enfuvirtide and T-1249 were measured in a
Langmuir-Blodgett trough NIMA ST900 (Coventry, UK), at
constant temperature (2560.5uC). The surface of a HEPES buffer
solution contained in a Teflon trough of fixed area was
exhaustively cleaned by surface aspiration. Then, a solution of
lipids in chloroform was spread on this surface, reaching a surface
pressure of 20.561 mN/m. Peptide solutions were injected in the
subphase and the changes on the surface pressure were followed
during the necessary time to reach a constant value. The surface
pressure of an air2water interface upon injecting the largest
concentration of each peptide used throughout the studies was
always below 15 mN/m (data not shown). For this reason, the
lowest initial surface pressure of the lipid monolayers before the
addition of the peptides to the subphase was above that value. In
this condition, the changes in surface pressure observed upon the
injection of the peptide can be attributed to an effect of the peptide
on the monolayer interfacial tension.
The dissociation constant (Kd) was calculated from the
adsorption Langmuir isotherm:
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where DP are the changes of surface pressure, DPmax is the
maximum change of pressure achieved and [peptide] is the peptide
concentration.
Acrylamide Quenching
The fluorescence quenching of 5 mM C34 or C34-cholesterol by
acrylamide (0260 mM) [8] was studied in buffer and in the
presence of POPC or DPPC 3 mM LUV, by successive additions
of small volumes of the quencher stock solution. For every
addition, a minimal 10 min incubation time was allowed before
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where I and I0 are the fluorescence intensity of the sample in the
presence and absence of quencher, respectively, KSV is the
Stern2Volmer constant and [Q] the concentration of quencher.
5NS and 16NS Quenching
Fluorescence quenching assays with the lipophilic probes 5NS
and 16NS were performed by time-resolved fluorescence spec-
troscopy. These assays were carried out at the same peptide and
lipid concentrations used for the acrylamide quenching, by
successive additions of small amounts of these quenchers (in
ethanol) to samples of peptide in POPC and POPC:Chol (2:1),
keeping the ethanol concentration below 2% (v/v) [26]. The
effective lipophilic quencher concentration in the membrane was
calculated from the partition coefficient of both quenchers to the
lipid bilayers [27]. For every addition, a minimal 10 min
incubation time was allowed before measurement. Quenching
data were analyzed by using the Stern2Volmer equation (eq. 1),
or the Lehrer equation [27,28] when a negative deviation to the
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where fb is the fraction of light arising from the fluorophores
accessible to the quencher.
In the case of dynamic quenching, the relationship I0/I = t0/t is
valid; thus, time-resolved quenching data can be analyzed by using
the same equations (eq. 3 and 4).
Membrane Dipole Potential Assessed by di-8-ANEPPS
Human blood samples were obtained from healthy volunteers,
with their previous written informed consent, at the Instituto
Português do Sangue (Lisbon, Portugal). This study was approved
by the ethics committee of the Faculdade de Medicina da
Universidade de Lisboa. Isolation of erythrocytes and PBMC and
labeling of these cells with di-8-ANEPPS (Invitrogen, Carlsbad,
CA, USA) were performed as described before [9,29]. For
erythrocytes isolation, blood samples were centrifuged at 1200 6
g during 10 min, plasma and buffy-coat were removed, and
remaining erythrocytes were washed twice in working buffer. They
were incubated at 1% hematocrit in buffer supplemented with
0.05% (m/v) Pluronic F-127 (Sigma) and di-8-ANEPPS 10 mM.
PBMC were isolated by density gradient using Ficoll-Paque Plus
(GE Healthcare, Little Chalfont, UK) and counted in a Neubauer
improved hemocytometer. They were incubated at 3000 cells/mL
in Pluronic-supplemented buffer with 3.3 mM di-8-ANEPPS. Cells
were incubated with the fluorescent probe during 1 h, with gentle
agitation, and unbound probe was washed with Pluronic-free
buffer on two centrifugation cycles. C34, C34-cholesterol (in
DMSO stock solution) or cholesterol (in DMSO:ethanol 1:1 stock
solution) were incubated with erythrocytes at 0.02% hematocrit
and with PBMC at 100 cells/mL during 1 h, with gentle agitation,
before the fluorescence measurements. For lipid vesicles labeling,
suspensions with 500 mM of total lipid were incubated overnight
with di-8-ANEPPS 10 mM, to ensure maximum incorporation of
the probe. The maximum concentration of DMSO or
DMSO:ethanol in the suspensions was 2.4% (v/v) at 6 mM of
peptide or cholesterol. Excitation spectra and the ratio of
intensities at the excitation wavelengths of 455 and 525 nm
(R = I455/I525) were obtained with emission set at 670 nm to avoid
membrane fluidity-related artifacts [30,31]. Excitation and emis-
sion slits for these measurements were set to 5 and 10 nm,
respectively. The variation of R with the peptide concentration







with the R values normalized for R0, the value in the absence of
peptide. Rmin defines the asymptotic minimum value of R and Kd is
the dissociation constant.
Data Analysis
Fitting of the equations mentioned in this article to the
experimental data was done by non-linear regression using
Graphpad Prism 5. Error bars on data presentation represent
the standard error of mean (SEM).
Results
Membrane Partition
UV-visible absorption and fluorescence spectra in buffer of C34
are comparable to those of Trp in aqueous solution (Fig. 1);
however, C34-cholesterol presents a blue shift, indicating that
there is a change in the Trp surrounding environment in this
conjugate.
As shown in Fig. 2, there is an increase in the fluorescence
intensity of C34-cholesterol in the presence of LUV. The partition
coefficient between the lipid and aqueous phases, Kp, was
determined by fitting eq. 1 to the fluorescence intensity data, in
order to quantify the extent of interaction of the peptides to the
LUV (Table 1). For POPC, a lipid with packing density and
fluidity properties similar to biological membranes, a Kp value of
1.576103 was obtained, showing a significant interaction. When
gel phase DPPC membranes were tested, a decreased Kp was
found, probably due to the higher bilayer rigidity. In cholesterol-
rich membranes (POPC:Chol, POPC:Chol:SM 2:2:1 and HIV-
like mixture) a significant increase in the partition was observed,
when compared with pure POPC, also with a decrease on IL.
Mixtures with cholesterol and SM mimic membrane microdo-
mains usually named lipid rafts [33]. The same variation on IL
occurred for the addition of SM or DHSM (an unusual
sphingolipid which does not contain a 4,5-trans double bond in
its sphinganine backbone, significantly enriched in HIV-1
membranes [22]). The HIV-like mixture had the highest partition,
C34-Cholesterol Membrane Interactions
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hinting to an importance of the viral membrane in capturing the
drug besides the cell membrane.
In the case of C34, except for DPPC, no significant changes in
the fluorescence intensity were observed in the presence of
membranes (Fig. 2A), indicating an absence of significant peptide-
membrane interactions.
Surface Pressure Perturbation of Monolayers
Despite the negligible partition and quenching results, adsorp-
tion of C34 to the membrane surface cannot be discarded, as it
may leave the Trp residues exposed to the bulk aqueous
environment, with unchanged quantum yield (i.e., not contributing
for Kp calculation) [10]. In order to discard that situation, surface
pressure measurements on POPC monolayer were carried out,
using a low initial surface pressure (20.5 mN/m). Usually, the
adsorption and penetration of molecules is favored at low surface
density (loosely packed lipid monolayers), whereas high surface
pressure (compact lipid packing) hinders the adsorption and
penetration in the lipid monolayers [34]. As shown in Fig. 3A, C34
is not able to induce any significant change in the surface pressure,
in contrast to C34-cholesterol.
We also measured the changes in surface pressures induced by
enfuvirtide and T-1249, yielding similar results to C34-cholesterol
(Fig. 3A). In contrast, with POPC:Chol (2:1) or POPC:Chol:SM
(1:1:1) monolayers, C34-cholesterol was able to induce larger
changes than the other inhibitors (Figure 3B,C). Kd and DPmax
values were determined by fitting eq. 2, in order to quantify the
interaction of each peptide with the Langmuir monolayers
(Table 2).
Direct comparison between the three peptides is difficult since
they have different membrane binding domains. Therefore, they
are not expected to modify the same way the surface tension of the
membrane. However, comparing the same peptide for different
lipids, we observe that C34-cholesterol presents an increased
affinity to cholesterol rich membranes: an approximate ten-fold
increase for POPC:Chol (2:1) and around six-fold for POPC:-
Chol:SM (1:1:1), when compared to pure POPC. This is in good
agreement with data obtained from partition studies. In the case of
enfuvirtide, no significant changes in the affinity were observed
among each membrane composition tested, with just a slight
decrease in the affinity for POPC:Chol, in a good agreement with
previously published data [35]. Finally, T-1249 presented lower
affinity for POPC:Chol, when compared with the other two
compositions.
When the interaction kinetics were tested, a faster variation was
observed for C34-cholesterol (Figure 3D). Control experiments
were carried out using DMSO without C34-cholesterol and no
significant changes were observed.
Localization in the Lipid Bilayer
In order to test the accessibility of the fluorophores to the
aqueous environment, the fluorescence quenching of the Trp
residues of the peptide by acrylamide was studied. Linear Stern-
Volmer plots were obtained in the absence of lipid (Fig. 4) and the
quenching for C34-cholesterol is less efficient than C34, indicating
that the fluorophore in the conjugate is less exposed to the
surrounding aqueous medium. The cholesterol moiety may create
hydrophobic pockets due to the formation of micro-aggregates,
leading to this difference in the quenching in aqueous solution.
Stern2Volmer plots and Ksv constants in the presence of 3 mM of
lipid and 5 mM of C34 or C34-cholesterol were obtained in order
to complement the partition assays (Fig. 4). For C34-cholesterol,
both assays with lipids yielded Ksv values lower than the obtained
in their absence (7.2360.15 mM21 in solution, 5.5860.14 mM21
with DPPC and 5.1660.11 mM21 with POPC). In contrast, for
C34 only, DPPC was able to reduce the Ksv value from
Figure 1. Characteristics of C34 and C34-cholesterol. (A) Schematic representation of HIV-1 gp41 main domains, depicting the relative
position of the fusion peptide (FP), N-terminal heptad repeat domain (NHR), C-terminal heptad repeat domain (CHR) and transmembrane region (TM).
The sequence of C34 was aligned with enfuvirtide, T-1249 and sifuvirtide, showing the pocket binding domain (PBD) and the lipid binding domain
(LBD). Hydrophobic residues are represented in blue, non-charged polar residues in green, and charged polar residues in red. (B) Normalized
fluorescence excitation (dashed line) and emission (solid line) spectra of 5 mM C34, C34-cholesterol or Trp in aqueous solution.
doi:10.1371/journal.pone.0060302.g001
Table 1. Partition coefficients.
Lipid Mixture Kp IL/Iw
POPC 15746261 1.8860.05
DPPC 331644 2.9860.16
POPC:Chol 2:1 34546718 1.2560.01
POPC:Chol:SM 2:2:1 40506885 1.2460.01
POPC:Chol 1:1 46126436 1.3260.01
POPC:DHSM (6%) 7556232 1.7260.09
HIV-like mixture 808461190 1.1460.004
HIV-like mixture with DHSM 17586688 1.1560.002
Parameters obtained from the fitting of the fluorescence data of the partition
assays of C34-cholesterol 5 mM using eq. 1. All measures were made at least in
triplicate. Values are presented as mean 6 standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.t001
C34-Cholesterol Membrane Interactions
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13.660.01 mM21 in solution to 11.560.39 mM21 in DPPC
vesicles. These reductions on the Stern2Volmer constant indicate
that the interaction with the membrane occurs with the
fluorophores partially exposed to the aqueous environment.
Fluorescence quenching measurements were also used to
evaluate the depth of insertion of Trp residues of the peptides
inserted in POPC or POPC:Chol (2:1) vesicles. Stearic acid
molecules derivatized with doxyl (quencher) groups either at
carbon 5 (5NS) or 16 (16NS) were used. 5NS is a better quencher
for molecules inserted in the membrane in a shallow position, close
to the lipid-water interface, while 16NS is better for molecules
buried deeply in the membrane [36]. Fig. 5A and B shows the
Stern-Volmer plot obtained for C34-cholesterol on POPC or
POPC:Chol (2:1), respectively, using the effective concentration of
5NS and 16NS in the bilayer matrix. For POPC, the Ksv with 5NS
was higher (4.4360.41 mM21, calculated with the Lehrer
equation) than for 16NS (1.3860.052 mM21, calculated with
the linear Stern-Volmer equation). In the case of POPC:Chol
(2:1), Ksv for 5NS was also higher (9.2360.67 mM
21, with the
Lehrer equation) than 16NS (6.9460.44 mM21, with the Lehrer
equation). Fluorescence lifetime quenching data enabled the
application of the SIMEXDA method [36] to obtain the depth
of insertion of the Trp residues of C34-cholesterol (Fig. 5C). A
similar mean shallow location, close to the membrane interface,
was observed for both lipid membranes. However, in the presence
of cholesterol, the depth distribution is narrower, and the location
more superficial (more exposed to the aqueous media), in a good
agreement with acrylamide quenching data. The location distri-
bution of C34-cholesterol does not differ much from the
determined previously for enfuvirtide or T-1249 [10,35]. As
expected, no changes in the fluorescence intensity were detected in
the presence of 5NS or 16NS for C34 (data not shown).
Interaction with Blood Cell Membranes
After the characterization using membrane-model systems, we
studied this peptide-membrane interaction in biological settings.
We used isolated human erythrocytes and PBMC, labeled with
the fluorescent probe di-8-ANEPPS, which is sensitive to the
membrane dipole potential [30]. If the peptides interact by
inserting or adsorbing on the membrane, it is expected that they
change the membrane order to some extent, inducing variations
in its dipole potential. These changes can be reported by di-8-
ANEPPS excitation spectrum shifts [30,37], becoming easier to
assess in differential spectra (Fig. 6A–C). The fluorescence red
shift indicates a decrease in the membrane dipole potential in a
peptide concentration-dependent manner. In order to quantify
this interaction, we measured the ratio R of the intensities at the
excitation wavelengths 455 and 525 nm (with emission at
670 nm) for a range of peptide concentrations. R is a
quantitative descriptor of spectral shifts and, hence, of the
relative variation of dipole potential. The membrane dipole
potential significantly decreased in the presence of C34-
cholesterol (Fig. 6 D–F), in sharp contrast to the unconjugated
C34 peptide that had almost no effect. This shows that, in
agreement with the model membrane studies, C34 does not
have tendency to interact with cell membranes, while C34-
cholesterol does. Affinity constants derived from the dipole
potential variation curves indicate a much higher affinity when
compared with the previously studied HIV fusion inhibitor
peptides enfuvirtide and T-1249 (Table 3).
For the sake of comparison with the data obtained for blood cell
membranes, and in order to validate the comparison with previous
data, we also labeled lipid vesicles with di-8-ANEPPS (Fig. 6A, D).
Lipid vesicles were composed of POPC, POPC:Chol 2:1 and
POPC:Chol 1:1. In a good agreement with the partition and
pressure data, we found that the increase of the cholesterol
percentage on the membrane also increased the interaction of
C34-cholesterol. Additions of DMSO, cholesterol or C34 were
also tested as control and no changes on the dipole potential were
observed (data not shown).
Discussion
In previous works, we showed that the interaction of HIV fusion
inhibitor peptides with membranes (using lipid membrane models
Figure 2. Partition of the peptides to lipid vesicles. Evaluation of Trp fluorescence variations of 5 mM C34 (A) or C34-cholesterol (B) upon
titration with large unilamellar vesicles (LUV), performed by successive additions of POPC, POPC:Chol 2:1, DPPC or HIV-like mixture LUV suspension.
Dashed lines are fittings of eq. 1 to the experimental data.
doi:10.1371/journal.pone.0060302.g002
C34-Cholesterol Membrane Interactions
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and blood cells) is a key aspect of their mechanism of action. The
membranotropic properties of a peptide can increase its local
concentration at the membrane and boost the efficiency of the
drug [8–10,29,35,38]. In this context, we studied the membrane
interactions of the C34 peptide, in comparison with its cholesterol
conjugated version, C34-cholesterol, in order to understand the
Figure 3. Interaction of the fusion inhibitor peptides with lipid monolayers. (A2C) Changes in surface pressure as a function of HIV-1
fusion inhibitor addition to pure POPC (A), POPC:Chol 2:1 (B) or POPC:Chol:SM 1:1:1 (C) monolayers. Dashed lines are fittings of eq. 2 to the
experimental data. (D) Changes in surface pressure as a function of time after addition of HIV fusion inhibitors to achieve a final concentration of
31 nM on a POPC:Chol 2:1 monolayer. All assays were carried out at 25uC, using an initial pressure of 21.560.5 mN/m. Each point is the average of at
least triplicates of independent samples. Error bars represent the standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.g003














POPC 59615 3.560.3 3163.7 3.160.1 1260.6 3.360.02
POPC:Chol (2:1) 5.361.4 2.560.05 4166.8 1.460.06 6563.5 1.960.03
POPC:Chol:SM (1:1:1) 9.261.3 2.660.02 2764.6 1.660.03 1361.1 1.860.02
Parameters obtained from the fitting of the surface pressure data from Fig. 3 using eq. 2. All measures were made at least in triplicate. Values are presented as mean 6
standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.t002
C34-Cholesterol Membrane Interactions
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molecular basis of the dramatically increased antiviral efficiency of
the conjugate [11].
This study demonstrates the membrane-binding ability of C34-
cholesterol. Overall the results obtained from partition, surface
pressure, quenching and dipole potential show that the addition of
the cholesterol moiety to the C-terminus of C34 renders the
peptide membranotropic. The partition coefficients for POPC
obtained for this conjugated peptide are of the same order as the
previously determined for enfuvirtide and T-1249 (Table 1). In
contrast, C34 shows no partition for membranes of this lipid.
Enfuvirtide and C34 share a common CHR sequence as a
structural domain; however, C34 lacks a putative lipid-binding
domain (LBD) that is Trp rich, which may explain its low
membrane partition (Fig. 1A) [39]. This is also the case of the
LBD-lacking fusion inhibitor peptide sifuvirtide, which also
presents residual binding to POPC vesicles and the same
preference for DPPC membranes (on the gel phase) [8,29]. When
the interactions with cholesterol-rich membranes were studied, in
contrast with the result previously obtained for enfuvirtide [35],
membrane partition of C34-cholesterol still takes place and with a
relatively high Kp (Table 1). A similar behavior was found for lipid
raft-mimicking membranes (POPC:Chol:SM).
In order to interpret results on POPC:Chol binary mixtures,
their phase diagram at 25uC needs to be considered [33]. In the
case of pure POPC, the membrane is in the liquid disordered
phase (Ld). For POPC:Chol 2:1 there is a phase coexistence
between liquid ordered (Lo) and liquid disordered (Ld) phases,
while for POPC:Chol 1:1 only Lo phase occurs (but close to the
Figure 4. Accessibility of the peptide to the aqueous medium. Fluorescence quenching by acrylamide of C34 (A) and C34-cholesterol (B) in
the presence (filled symbols) and absence (empty circles) of lipid vesicles (5 mM peptide and 3 mM total lipid). Lipid compositions tested were pure
POPC, POPC:Chol 2:1 and pure DPPC. Dashed lines are fittings of the Stern-Volmer equation (eq. 3) to the experimental data.
doi:10.1371/journal.pone.0060302.g004
Figure 5. Localization of C34-cholesterol in the bilayer. (A–B) Stern-Volmer plots for the quenching of C34-cholesterol fluorescence by 5NS or
16NS in POPC (A) and POPC:Chol 2:1 (B) LUV, using time-resolved fluorescence measurements. Each point is the average of three independent
measures. The dashed lines are fittings of the Lehrer equation (eq. 4) to the experimental data, except for 16NS in POPC (eq. 3). (C) Depth of insertion
of C34-cholesterol Trp residues in the membrane using SIMEXDA method [36], yielding an average location 16.8 Å away from the center of the bilayer
for POPC and 18.0 Å for POPC:Chol 2:1. Distributions’ half-width at half-height were 8.9 Å for POPC and 6.5 Å for POPC:Chol.
doi:10.1371/journal.pone.0060302.g005
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boundary between Lo/Ld coexistence). Our partition data indicate
that C34-cholesterol preferentially partitions to the Lo phase,
displaying a Kp three-fold higher than for the Ld phase (pure
POPC), and an intermediate behavior when both Ld and Lo
phases coexist. Additionally, using di-8-ANEPPS labeled LUV
(Fig. 6A, D), we showed that the interaction of the conjugated
peptide increases with the amount of cholesterol present in the
POPC:Chol binary mixture, suggesting again a preference for
cholesterol-rich membranes.
Surface pressure measurements (Fig. 3) showed a higher
membrane affinity of C34-cholesterol towards cholesterol and
SM-rich membranes, when compared to pure POPC. Taking into
account that C34 was unable to induce any change in any of the
tested monolayers (data not show) these experiments also showed
that the cholesterol moiety boosts the adsorption of C34
specifically on cholesterol-rich membranes. In comparison, en-
fuvirtide showed much less distinction between the three mixtures
tested. Furthermore, regarding the kinetics of the interactions of
the three HIV fusion inhibitors in POPC:Chol monolayers
(Fig. 3D), we found that C34-cholesterol also exhibit a faster
binding kinetic, which could only be assigned to the ‘‘membrane
anchoring’’ cholesterol moiety.
This preference of the drug for cholesterol and ‘‘lipid raft-like’’
mixtures is very relevant regarding inhibiting HIV entry. The
most important receptors for HIV entry, CD4 and CCR5, were
shown to be associated with lipid raft microdomains and DRM
(detergent resistant membranes) and this association is important
for the binding of the virus to cells [40]. Several studies also
demonstrated that depleting cholesterol from the host cells greatly
Table 3. Antiviral activity and cell membrane interaction
parameters compared of HIV-1 fusion inhibitors.
C34-cholesterol T-1249 Enfuvirtide (T-20)
IC90
(nM)*
JRFL 0.36 8.3 20
NL4-3 0.09 2.6 6.1
Kd (mM) Erythrocytes 0.5860.049 4.1660.13
{ 35.461.33{




Figure 6. Peptide interactions with di-8-ANEPPS labeled LUV and cell membranes. (A–C) Differential spectra of di-8-ANEPPS bound to LUV
(A) erythrocytes (B) and PBMC (C) membranes in the presence of C34-cholesterol and in its absence. Spectra were obtained by subtracting the
excitation spectrum (normalized to the integrated areas) of labeled cells in the presence of peptide from the spectrum in the absence of the
respective peptide. The shift to the red (decrease in dipole potential) is peptide concentration-dependent. For LUV, spectra traces represent C34-
cholesterol 4 mM, in the presence of different lipid compositions: POPC, POPC:Chol 2:1 and POPC:Chol 1:1. For cells, spectra traces represent different
C34-cholesterol concentrations: 0 mM, 0.25 mM, 1 mM and 5 mM. (D) Binding profiles of C34-cholesterol to LUV of POPC, POPC:Chol 2:1 and POPC:Chol
1:1, by plotting the di-8-ANEPPS excitation ratio, R (I455/I525, normalized to the initial value), as a function of the peptide concentration. DMSO,
cholesterol and C34 (unconjugated) were also tested, as controls, and no significant changes on the dipole potential were observed (data not shown).
(E–F) Binding profiles of C34-cholesterol, C34 and cholesterol to erythrocytes (E) and PBMC (F) cell membranes. Controls for DMSO (empty circles)
and DMSO:ethanol (empty square) were also performed. Dashed curves represent the fitting to the single binding site equation (eq. 5). Affinity
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inhibits HIV infection [40–42]. Moreover, the substitution of the
virion-associated cholesterol by the raft-inhibiting sterol analogues
4-cholestenone and coprostanol was shown to reduce infectivity, in
contrast to other raft promoting sterols [43]. Overall, lipid rafts are
considered to be essential for the virus entry process [44]. The
preferential partition of C34-cholesterol to those domains would
make the drug more available at the site where membrane fusion
occurs.
Recently, the lipid composition of HIV-1 membrane, consti-
tuting its lipidome, has been precisely determined [22]. That
allowed us to study lipid vesicles with compositions mimicking the
virus envelope. The high C34-cholesterol partition observed for
the HIV membrane-like mixture of lipids indicates that the viral
membrane itself can also extensively capture and carry the
conjugate drug on its surface, enhancing its availability at the
required site of action. However, this interaction seems to be
sensitive to the presence of DHSM, a lipid found to be unusually
enriched at the viral membrane, when compared to the host cell
membrane [22]. When present, DHSM decreases C34-cholesterol
partition (Table 1). It is tempting to speculate that, in a context of
virus and host cell engagement; this may be a factor that shifts the
equilibrium of partition towards the cell membranes, where it
anchors in the right direction to interact with the transiently
exposed gp41 NHR domain.
Regarding the location of C34-cholesterol at the membrane
level, our data show that the Trp residues of the peptide insert in
the external leaflet of the bilayer, at a shallow position. Previously,
the Trp-rich regions of enfuvirtide and T-1249 were also shown to
insert superficially in lipid bilayers [10,35]. As the peptide is
conjugated with cholesterol in a defined position, the peptide
should adopt a consistent orientation, with the C-terminus
anchored to the membrane by the cholesterol moiety (Fig. 1A).
This is the proper orientation to align in an anti-parallel fashion
with the NHR domain of gp41 when it extends towards the target
membrane. The N-terminus, where the Trp residues are located,
may interact freely with the nearby lipids, but cannot insert deep
in the membrane.
In order to have a better understanding of what may happen in
the bloodstream, we also studied the interaction of the peptides
with human erythrocytes and mononuclear leukocytes. These
peptide drugs must be injected, as oral administration is not
feasible. HIV-1 is known to associate to the surface of erythrocytes
in circulation [45–47], while PBMC are among the virus main
targets. C34-cholesterol decreases the membrane dipole potential
of the two cell types, indicating that an interaction is occurring
(Fig. 6). In agreement with the partition data, C34 alone also does
not interact with cell membranes. The same concentration of
cholesterol alone is not sufficient to induce a detectable membrane
potential change [48], indicating that the potential change is
induced essentially by the peptide component of the conjugate.
However this change only occurs in the conjugate, emphasizing
the role of cholesterol in inducing the membrane partition of the
peptide to cell membranes.
Quantitatively, C34-cholesterol was found to have approxi-
mately 115 or 14 times more affinity towards PBMC membranes
than enfuvirtide or T-1249, respectively. Furthermore, the cell
membrane affinities of the different fusion inhibitor peptides (C34-
cholesterol.T-1249. enfuvirtide) correlate with the antiviral
potency against HIV-1 (Table 3). Regarding the comparison with
the Kp values determined with lipid vesicles, this is not
straightforward, as the results obtained for the different compo-
sitions tested indicate that the process is lipid composition-
dependent. Moreover, the partition is based on tryptophan
fluorescence, which regards only the peptide part of the conjugate.
Figure 7. Putative mode of action of HIV-1 fusion inhibitor C34-cholesterol. In aqueous solution, the conjugate may form micro-aggregates
when membranes are not present, due to its cholesterol moiety. The drug was demonstrated to partition to cell membranes and virus-like
membranes. A preference towards cholesterol and SM-rich compositions was identified. These lipids are characteristic of the membrane
microdomains designated as lipid rafts, which usually contain the receptors involved in HIV entry. C34-cholesterol anchors to the membrane via its
cholesterol moiety and also, with a putative weaker binding, via its Trp (W)-rich N-terminal domain. In the context of HIV-1 gp41 engagement with
the target cell, a confined space exits between the two membranes. Enrichment in DHSM in the viral membrane decreases the peptide partition,
possibly shifting membrane partition equilibrium to the host cell membrane. The drug concentrated in the lipid raft environment may reach its target
(gp41) more efficiently than through simple diffusion in aqueous solution. Moreover the anchoring promoted by the cholesterol at the C-terminus
brings the peptide into contact in the correct orientation to compete with NHR binding site. This way, gp41 mediated fusion may be inhibited,
blocking viral content entry into the cell.
doi:10.1371/journal.pone.0060302.g007
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However, if we focus on cholesterol-containing mixtures, C34-
cholesterol has the highest partition, contrasting with enfuvirtide,
with negligible interaction [35]. T-1249 should fall in between,
considering its partition to cholesterol-poor domains and ability to
adsorb on cholesterol-rich domains [10].
These findings, relating membrane binding to improved
antiviral potency of the peptides, indicate that this is a major
factor to take into account when rationally designing HIV fusion
inhibitor peptides. We demonstrated that C34-cholesterol has
membranotropic behavior towards lipid vesicles and strongly
interacts with circulating blood cells membranes. HIV fusion
inhibitors have a restricted temporal and spatial window of
opportunity to bind to their molecular target: the NHR region of
gp41 in its extended conformation, when the virus and target cell
are closely engaged. This makes aqueous diffusion of the peptide
to its target less efficient. It has also been demonstrated that the
forces governing protein–protein interactions in a membrane
environment are different from those in solution [49]. The ability
that these peptides have to bind to cell membranes facilitates the
delivery of the peptides to this confined environment, as some
peptide is already locally present (Figure 7). In this context, C34-
cholesterol should be able to concentrate at the cell surface and
also on the viral membrane. In agreement with this, previous
results with cells after 48 h of treatment with C34-cholesterol
showed the persistence of antiviral activity of residual peptide not
cleared by washing steps [11], supporting the idea that cell
membranes could work as C34-cholesterol reservoir. Importantly,
the concentration effect would be higher on the lipid rafts, where
the HIV receptors are present and fusion is more likely to occur
[40,44]. This persistent antiviral activity may be ideal for this drug
to be applied as a topical microbicide, for example as vaginal gel,
to prevent infection [12]. C34-cholesterol was generally the most
active inhibitor when tested in the context of human mucosal
tissue explants (colorectal, penile and cervical), when compared to
C34, enfuvirtide and T-1249 [12]. The first microbicides
formulations against HIV were based on unspecific polyanions
to present viral attachment to the cell surface; however, they
largely failed in clinical trials [50]. Only recently a trial using a
tenofovir gel (a reverse transcriptase inhibitor) showed 39%
reduction on HIV-1 infection [51]. Using an entry inhibitor such
as C34-cholesterol could prevent the viral entry in the first
encountered immunological cells of the mucosa, blocking the virus
at the earliest stage of infection.
Ultimately, the membrane may act as a ‘‘catalyst’’ to the
binding reaction between gp41 and the peptide inhibitors, as it has
been postulated in other receptor-ligand scenarios in membrane
environments [38]. Thus, in this case, the marked increase in
antiviral efficiency of C34-cholesterol in relation to C34 (and other
fusion inhibitors) correlates with its higher affinity towards model
and blood cells membranes.
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